Provided By GlobeNewswire
Last update: May 19, 2025
- Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -
Read more at globenewswire.comNASDAQ:DRTSW (6/26/2025, 1:48:19 PM)
0.2498
0 (-0.04%)
NASDAQ:DRTS (6/26/2025, 2:13:22 PM)
3.0696
+0.07 (+2.32%)
Find more stocks in the Stock Screener